Anlotinib combined with first-generation EGFR-TKI in comparison with TKI alone in patients with advanced NSCLC with EGFR mutation positive and slow progression after TKI therapy
Latest Information Update: 24 Jun 2019
At a glance
- Drugs Catequentinib (Primary) ; Protein tyrosine kinase inhibitors
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- 02 Nov 2018 New trial record